JPRN-UMIN000003682已完成3 期
A Phase III randomized controlled clinical trial of CARBOPLATIN and PACLITAXEL(OR GEMCITABINE) alone or in combination with BEVACIZUMAB (NSC #704865, IND #7921) followed by BEVACIZUMAB and secondary cytoredutive surgery in platinum sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer. - GOG-0213
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,050
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)More than 1 previous regimen of chemo 2)Receiving concurrent immunotherapy or radiotherapy 3)Prior radiotherapy to any portion of the abdominal cavity or pelvis 4)Evidence of partial bowel obstruction or perforation 5)Prior chemo for any abdominal or pelvic tumor 6)Synchronous primary endometrial cancer, or a past history of primary endometrial cancer 7)Secondary cytoreduction for recurrent disease 8)Uncontrolled infection 9)Concurrent severe medical problems unrelated to the malignancy 10)More than grade2 peripheral neuropathy 11)History of allergic reactions to carboplatin and/or paclitaxel or chemically similar compounds. 12)Hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies. 13)Childbearing potential, not practicing adequate contraception, pregnant or nursing 14)Other invasive malignancies, with the exception of non-melanoma skin cancer, within the last 5 yrs 15)Active bleeding or pathologic conditions that carry high risk of bleeding 16)History or evidence upon physical examination of CNS disease 17)Significant cardiac conduction abnormalities 18)Uncontrolled hypertension, defined as systolic >150mmHg or diastolic >90mmHg 19)Myocardial infarction, cardiac arrhythmia or unstable angina < 6mo prior to registration 20)NYHA Grade2 or greater congestive heart failure 21)Serious cardiac arrhythmia requiring medication 22)Grade2 or greater peripheral vascular disease 23)History of CVA within 6mo 24)Patients who have had a major surgical procedure, open biopsy, dental extractions or other dental surgery/procedure that results in an open wound, or significant traumatic injury within 28days prior to the treatment on this study, or anticipation of need for major surgical procedure during the course of the study; patients with placement of vascular access device or core biopsy within 7days prior to the treatment on this study.
研究者
相似试验
进行中（未招募）
1 期
Phase III Randomized Controlled Trial of Pembrolizumab with or without Chemo vs Chemo in Advanced Urothelial CarcinomaAdvanced or Metastatic Urothelial CarcinomaMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2015-005731-41-IEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.990
已完成
3 期
A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinomabladder cancerNL-OMON45288Merck Sharp & Dohme (MSD)20
进行中（未招募）
1 期
Phase III Randomized Controlled Trial of Pembrolizumab with or without Chemo vs Chemo in Advanced Urothelial CarcinomaAdvanced or Metastatic Urothelial CarcinomaMedDRA version: 19.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2015-005731-41-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.990
进行中（未招募）
1 期
Phase III Randomized Controlled Trial of Pembrolizumab with or without Chemo vs Chemo in Advanced Urothelial CarcinomaAdvanced or Metastatic Urothelial CarcinomaMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2015-005731-41-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.990
进行中（未招募）
1 期
Phase III Randomized Controlled Trial of Pembrolizumab with or without Chemo vs Chemo in Advanced Urothelial CarcinomaAdvanced or Metastatic Urothelial CarcinomaMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2015-005731-41-BEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.990